<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0005547'>Myeloproliferative disorders</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e>) represent a subcategory of <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> and are characterized by a stem cell-derived clonal proliferation of myeloid cells including erythrocytes, platelets, and leucocytes </plain></SENT>
<SENT sid="1" pm="."><plain>Traditionally, the term '<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e>' included <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>), <z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e>), <z:e sem="disease" ids="C0040028" disease_type="Disease or Syndrome" abbrv="">essential thrombocythemia</z:e> (ET), and <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> with <z:mpath ids='MPATH_173'>myeloid metaplasia</z:mpath> (MMM) </plain></SENT>
<SENT sid="2" pm="."><plain>At present, these four disorders are referred to as 'classic' <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e> and are distinguished from a spectrum of other <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e>-like clinicopathologic entities that are operationally classified as 'atypical' <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>The oncogenic mutations(s) in classic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e> are unknown except for <z:mp ids='MP_0005481'>CML</z:mp>, which is associated with an activating mutation (Bcr/Abl) of the gene encoding for the Abl cytoplasmic protein kinase (PTK) </plain></SENT>
<SENT sid="4" pm="."><plain>In the last 3 months, a somatic point mutation of JAK2 (JAK2(V617F)), the gene encoding for another cytoplasmic PTK was reported in the majority of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e> and approximately half of those with either ET or MMM </plain></SENT>
<SENT sid="5" pm="."><plain>The same mutation was also found in a small number of patients with either atypical <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e> or the <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> but not in <z:mpath ids='MPATH_458'>normal</z:mpath> controls, germline tissue including T lymphocytes, and patients with secondary <z:hpo ids='HP_0001901'>erythrocytosis</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>In vitro, JAK2(V617F) was associated with constitutive phosphorylation of JAK2 and its downstream effectors as well as induction of erythropoietin hypersensitivity in cell lines </plain></SENT>
<SENT sid="7" pm="."><plain>In vivo, murine bone marrow transduced with a retrovirus containing JAK2(V617F) induced <z:hpo ids='HP_0001901'>erythrocytosis</z:hpo> in the transplanted mice </plain></SENT>
<SENT sid="8" pm="."><plain>Taken together, these observations suggest that JAK2(V617F) is an acquired myeloid lineage-specific mutation that engenders a pathogenetic relevance for the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e> phenotype in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e> </plain></SENT>
</text></document>